JPRN-UMIN000009174已完成未知
Effect of budesonide/formoterol in chronic obstructive pulmonary disease patients with low peak inspiratory flow rate - Effect of budesonide/formoterol in chronic obstructive pulmonary disease patients with low peak inspiratory flow rate
Department of Respiratory Medicine, Chiba-Hokusoh Hospital, Nippon Medical School0 个研究点目标入组 20 人开始时间: 2012年10月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Infections with no available effective antimicrobial drugs or with deep mycosis 2) A history of hypersensitivity (including contact dermatitis)to any ingredient contained in budesonide/formoterol 3) Tuberculosis 4) Case with the following complications a) Severe liver disease b) Severe renal disease 5) Planning-to-be-pregnant, pregnant or lactating patients 6) Inappropriate case considered by physician
研究者
相似试验
已完成
不适用
The effects of budesonide/formoterol maintenance and reliever therapy on airway inflammation in asthma patients; open label, randomized parallel group comparison study with fluticasone/salmeterolBronchial asthmaJPRN-UMIN000011241Hiroshima Allergy and Respiratory Clinic30
已完成
不适用
Effects of budesonide and formoterol combination on airway regulatory T cells in mild asthmaticsJPRN-UMIN000004275Division of respirology, neurology, and rheumatology, Department of medicine, Kurume University School of Medicine10
已完成
不适用
Clinical effects of budesonide/formoterol in patients with asthmaBronchial asthmaJPRN-UMIN000003745Atami Hospital International University of Health and Welfare30
已完成
不适用
Improved effects of Budesonide/Formoterol combination therapy (Symbicort) on the residual eosinophilic inflammation in the distal airways of asthmatic patients who used the salmeterol/fluticasone combination drugBronchial asthmaJPRN-UMIN000003805JA Tohno Kousei Hospital40
已完成
不适用
Study on the effects of the budesonide/formoterol combination formulation in improving airway inflammation and airway resistance in patients with bronchial asthmaPatients with bronchial asthma aged 20 years and older (males and females, outpatients and inpatients) being treated with an ICS (at a dose equivalent to FP 200-1000 mcg/day) and salmeterol 100 mcg/day in combination (either as two separate products or one combined product) for 3 months or longer with poor or inadequate controlJPRN-UMIN000006572Chiba-Hokusoh Hospital, Nippon Medical School80